Accelerated Publications
Subsite Specificity of Memapsin 2 (-Secretase): Implications for Inhibitor Design
²
Robert T. Turner III,
‡,§
Gerald Koelsch,
‡,|
Lin Hong,
‡,|
Pedro Castanheira,
‡,⊥
Arun Ghosh,
|,#
and Jordan Tang*
,‡,§,|
Protein Studies Program, Oklahoma Medical Research Foundation, and Department of Biochemistry and Molecular Biology,
UniVersity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, Zapaq, Inc.,
Oklahoma City, Oklahoma 73104, and Department of Chemistry, UniVersity of Illinois at Chicago, Chicago, Illinois 60607
ReceiVed May 30, 2001; ReVised Manuscript ReceiVed June 29, 2001
ABSTRACT: Memapsin 2 is the protease known as -secretase whose action on -amyloid precursor protein
leads to the production of the -amyloid (A) peptide. Since the accumulation of A in the brain is a key
event in the pathogenesis of Alzheimer’s disease, memapsin 2 is an important target for the design of
inhibitory drugs. Here we describe the residue preference for the subsites of memapsin 2. The relative
k
cat
/K
M
values of residues in each of the eight subsites were determined by the relative initial cleavage
rates of substrate mixtures as quantified by MALDI-TOF mass spectrometry. We found that each subsite
can accommodate multiple residues. The S
1
subsite is the most stringent, preferring residues in the order
of Leu > Phe > Met > Tyr. The preferences of other subsites are the following: S
2
, Asp > Asn > Met;
S
3
, Ile > Val > Leu; S
4
, Glu > Gln > Asp; S
1
′, Met > Glu > Gln > Ala; S
2
′, Val > Ile > Ala; S
3
′, Leu
> Trp > Ala; S
4
′, Asp > Glu > Trp. In general, S subsites are more specific than the S′ subsites. A
peptide comprising the eight most favored residues (Glu-Ile-Asp-Leu-Met-Val-Leu-Asp) was found to be
hydrolyzed with the highest k
cat
/K
M
value so far observed for memapsin 2. Residue preferences at four
subsites were also studied by binding of memapsin 2 to a combinatorial inhibitor library. From 10 tight
binding inhibitors, the consensus preferences were as follows: S
2
, Asp and Glu; S
3
, Leu and Ile; S
2
′, Val;
and S
3
′, Glu and Gln. An inhibitor, OM00-3, Glu-Leu-Asp-Leu*Ala-Val-Glu-Phe (where the asterisk
represents the hydroxyethylene tansition-state isostere), designed from the consensus residues, was found
to be the most potent inhibitor of memapsin 2 so far reported (K
i
of 3.1 × 10
-10
M). A molecular model
of OM00-3 binding to memapsin 2 revealed critical improvement of the interactions between inhibitor
side chains with enzyme over a previous inhibitor, OM99-2 [Ghosh, A. K., et al. (2000) J. Am. Chem.
Soc. 14, 3522-3523].
The accumulation of -amyloid peptide (A)
1
in the brain
is a major factor underlying the pathogenesis of Alzheimer’s
disease (AD) (1). A is a fragment of a brain membrane
protein -amyloid precursor protein (APP) produced by the
activity of two proteases known as - and γ-secretases.
-Secretase cleaves APP first in its lumenal domain and ²
This work was partly supported by NIH Grant AG-18933. R.T.T.
is a recipient of a Glenn/American Foundation for Aging Research
Scholarship. G.K. is a Scientist Development Grant Awardee of the
American Heart Association. J.T. is holder of the J. G. Puterbaugh
Chair in Biomedical Research at the Oklahoma Medical Research
Foundation.
* To whom correspondence should be addressed at the Oklahoma
Medical Research Foundation, 825 NE 13 St., Oklahoma City, OK
73104. Email: jordan-tang@omrf.ouhsc.edu. Tel: 405-271-7291.
FAX: 405-271-7249.
‡
Oklahoma Medical Research Foundation.
§
University of Oklahoma Health Sciences Center.
|
Zapaq, Inc.
⊥
Present address: Department of Biochemistry, University of
Coimbra, Coimbra, Portugal.
#
University of Illinois at Chicago.
1
Abbreviations: A, -amyloid peptide; APP, -amyloid precursor
protein; AD, Alzheimer’s disease.
© Copyright 2001 by the American Chemical Society Volume 40, Number 34 August 28, 2001
10.1021/bi015546s CCC: $20.00 © 2001 American Chemical Society
Published on Web 08/03/2001